Zynerba Pharmaceuticals Long-Term Debt 2011-2026 | ZYNE

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Annual Long-Term Debt Zynerba Pharmaceuticals

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
120 K	354 K	-	-	-	-	-	-	-	375 K	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
375 K	120 K	283 K

Quarterly Long-Term Debt Zynerba Pharmaceuticals

2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	60 K	120 K	179 K	237 K	296 K	354 K	411 K	468 K	525 K	-	-	-	44.2 K	110 K	110 K	110 K	110 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
525 K	44.2 K	224 K

Long-Term Debt of other stocks in the Drug manufacturers industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
AcelRx Pharmaceuticals ACRX	5.01 M	-	7.5 %	$ 6.35 M	USA
Adamis Pharmaceuticals Corporation ADMP	343 K	-	0.86 %	$ 117 M	USA
Aerie Pharmaceuticals AERI	21.8 M	-	-	$ 754 M	USA
Cumberland Pharmaceuticals CPIX	4.94 M	$ 3.1	-2.21 %	$ 43.6 M	USA
Cronos Group CRON	4.27 M	$ 2.58	-	$ 1.35 B	Canada
Harrow Health HROW	250 M	$ 35.13	-	$ 1.29 B	USA
Assertio Holdings ASRT	39.1 M	$ 19.26	-	$ 123 M	USA
Agile Therapeutics AGRX	1.52 M	-	10.11 %	$ 58.2 M	USA
Alimera Sciences ALIM	256 K	-	-	$ 142 M	USA
Athenex ATNX	93 K	-	-23.39 %	$ 1.76 M	USA
Avadel Pharmaceuticals plc AVDL	1.12 M	-	-	$ 2.06 B	France
Calliditas Therapeutics AB (publ) CALT	24.1 M	-	-0.1 %	$ 2.03 B	Schweden
Organogenesis Holdings ORGO	718 K	$ 2.24	-	$ 295 M	USA
HEXO Corp. HEXO	29 M	-	2.45 %	$ 38.1 M	Canada
Pacira BioSciences PCRX	585 M	$ 22.27	-	$ 1.03 B	USA
Bausch Health Companies BHC	21.9 B	$ 5.41	-	$ 1.97 B	Canada
Sundial Growers SNDL	16.2 M	$ 1.34	-	$ 3.37 M	Canada
Sonoma Pharmaceuticals SNOA	27 K	$ 2.33	-	$ 2.89 M	USA
OrganiGram Holdings OGI	104 M	$ 1.38	-	$ 402 M	Canada
Tilray TLRY	221 M	$ 6.66	-	$ 4.12 B	Canada
Aurora Cannabis ACB	295 M	$ 3.44	-	$ 86.3 M	Canada
Canopy Growth Corporation CGC	300 M	$ 1.02	-	$ 110 M	Canada
Veru VERU	2.92 M	$ 2.4	-	$ 324 M	USA
Viatris VTRS	18 B	$ 13.41	-	$ 16.1 B	USA
cbdMD YCBD	2.4 M	$ 0.73	-	$ 3.15 M	USA
Catalent CTLT	4.86 B	-	-	$ 11.5 B	USA
DURECT Corporation DRRX	16.7 M	-	-	$ 50.1 M	USA
Eagle Pharmaceuticals EGRX	56.2 M	-	-39.89 %	$ 27.7 M	USA
Endo International plc ENDP	8.15 B	-	-	$ 28.9 M	Irlanda
Evolus EOLS	146 M	$ 4.16	-	$ 268 M	USA
Emergent BioSolutions EBS	446 M	$ 8.1	-	$ 415 M	USA
Evoke Pharma EVOK	5 M	-	-	$ 36.6 M	USA
Jupiter Wellness JUPW	114 K	-	-	$ 33.6 M	USA
Lannett Company LCI	615 M	-	1.15 %	$ 7.11 M	USA
Neoleukin Therapeutics NLTX	5 K	-	-	$ 193 M	Canada
OptiNose OPTN	611 K	-	-	$ 1.08 B	USA
PetIQ PETQ	438 M	-	1.64 %	$ 400 M	USA
PLx Pharma PLXP	622 K	-	-27.8 %	$ 2.56 M	USA
ProPhase Labs PRPH	2.4 M	-	-	$ 5.07 M	USA
Radius Health RDUS	315 K	-	-	$ 1.42 B	USA
Recro Pharma REPH	339 K	-	-4.76 %	$ 65.3 M	USA
Relmada Therapeutics RLMD	2.66 M	$ 6.9	-	$ 272 M	USA
Rockwell Medical RMTI	8.83 M	$ 0.96	0.84 %	$ 34.5 M	USA
SCYNEXIS SCYX	1.69 M	$ 0.92	-	$ 45.9 M	USA
Solid Biosciences SLDB	19.1 M	$ 7.74	-	$ 677 M	USA
Zomedica Corp. ZOM	1.47 M	-	-0.21 %	$ 98 M	USA
Tricida TCDA	11.3 M	-	-	$ 3.25 M	USA
China Pharma Holdings CPHI	112 K	$ 0.61	-	$ 2.62 M	China
TherapeuticsMD TXMD	5.12 M	$ 2.2	-	$ 25.5 M	USA